Antoine Francis: LIFE – The Only Metric
Antoine Francis, Founder of Global Plasma Supply LTD, shared an insightful post on LinkedIn:
”From everywhere and anywhere I operate in the plasma industry, the numbers are more than statistics—they’re lives.
Every day, I think about:
The child in sub-Saharan Africa with hemophilia who may never reach adulthood because factor VIII isn’t available.
The mother in South Asia who survives childbirth only to face preventable complications because albumin was out of stock.
The patient with primary immunodeficiency in Southeast Asia who has never even heard of IVIG, let alone received it.
The science is clear. The solutions exist. But access is still dictated by postcode and purchasing power. That is not acceptable.
Through Global Plasma Supply LTD, we are pushing forward with strategies that unite operational excellence, ethical procurement, and a belief that every patient matters equally.
This is my life’s work, and it’s personal.
We will not stop until access to plasma-derived medicines is no longer a privilege but a given.”
Read the full article by Antoine Francis here.
Stay informed on the emerging in Hematology with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis